advanced biopharmaceuticals Flashcards

1
Q

peptide

A

a chain of amino acids, typically less than 50
produced with solid-phase synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

protein

A

a longer amino acid chain with secondary structure, typically over 50
production: 100-1000 liters, pilot plant, probes for pressure, biomass, carbon source, pH, dissolved O2, temperature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

post-translational modifications

A

hard to control
introduced enzymatically making them a challenge to reproduce –> reason why biologics are biosimilar and not generics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

common degradation pathways

A

deamination of asparagine residues
disulfide exchange

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

disulfide exchange

A

sulfide bonds on the protein are reshuffled and the catalytic base is regenerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

conditions that lead to degradation

A

high temperature
high/low pH
low temperature –> solute freezes and protein aggregates outside of ice
forced deamination
oxidation
photostability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

non-linear kinetics of fibrillation processes

A

can occur rapidly hours after shaking
lag –> elongation –> steady

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

lag phase

A

0 to 24 hours
system forming little seeds and proteins come together and grow into fibers; nucleation size are formed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

elongation phase

A

32 to 48 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

steady phase

A

56 to 72 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

biomimicry

A

mimic what nature is doing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

sugars like trehalose

A

stabilize protein formulations in the solution and the solid state
very high viscosity in glass state to freeze out motions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How can the derivatization of peptide/protein drugs enhance the half-life?

A

by binding albumin through a long hydrophobic tail attached to the insulin (reason why over 98% of insulin is bound to albumin in the blood)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

strategies to deliver peptide therapeutics via nonparental routes

A

intranasal delivery – Miacalcic and Synarel
permeation enhancer – SNAC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

intranasal delivery – Miacalcic and Synarel

A

drugs directly absorbed into circulation (avoid first pass metabolism)
drug can directly pass into the brain, avoid potential issues with needing to cross the BBB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

permeation enhancer – SAC

A

fluidizes the membrane
helps deliver peptides orally

17
Q

nonparental routes of delivery key considerations

A

high potency
wide variability
tolerability and safety
cost of goods (very expensive)

18
Q

primary mechanism responsible for RNA cleavage

A

the hydroxyl group on the 2’ position of the ribose sugar leads to the cleavage of the backbone

19
Q

why is RNA less stable toward backbone cleavage than DNA?

A

DNA does not contain an -OH in the 2’ position
replace the 2’ -OH group in RNA with another group (like NH2, F) leads to a more stable version

20
Q

shorter RNAs

A

particularly siRNA drugs
made with solid-supported chemical synthesis

21
Q

longer RNAs

A

particularly mRNA drugs with thousands of nucleotides
manufactured with cell free in vitro transcription

22
Q

why are modified nucleotides incorporated into RNA drugs?

A

to reduce immune reaction toward mRNA (like SpikeVax and COVID vaccines)
to stabilize the RNA

23
Q

n-methyl pseudouridine

A

modified nucleotide that replaces some uridines in some mRNA to reduce degradation and immune response
enzymes don’t recognize the modified nucleotide so a person does not elicit an immune response when receiving an mRNA vaccine (immune response would then be against a protein)

24
Q

MOA for siRNA drugs

A

degradation of specific complementary mRNA
the protein corresponding to the mRNA does not get synthesized while siRNA is present
galNAC-galactose N acetyl group attached to siRNA gets uptaken to extend half life

25
Q

How can exceptional stability and half-life be achieved with chemical modifications at the 2’-positions on the D-ribose sugars?

A

through replacing the 2’ -OH group with another functional group like F or OMe to prevent the degradation mechanism
this stabilized the RNA towards hydrolytic cleavage

26
Q

GalNAC ligand

A

in LEQVIO
targets the liver to degrade the mRNA of the PCSK9 enzyme
lowers cholesterol levels
high stability is made possible by a fully synthetic structure

27
Q

liver targeting

A

targeting ligands attached to the 3’ or 5’ ends of the RNAs can extend the half life of siRNAs

28
Q

biosimiliars

A

post translational modification (PTMs) make the difference between different types of biosimilars

29
Q

how does sugar stabilize proteins?

A

alcohol in the sugar replaces hydrogen bonds –> water is viscous and moves quickly –> sugar makes it like glass –> things cannot aggregate –> more stable